Abstract
OncoVEXGM-CSF is a second generation oncolytic HSV expressing GM-CSF. Deletion of ICP34.5 provides tumour selectivity, a modification extensively studied elsewhere. Compared to previous oncolytic HSV, oncolytic potency is increased using a clinical virus strain with greater lytic capabilities than previous laboratory strains, and by expressing US11 as an IE rather than an L gene. Immune stimulation is improved by deleting ICP47, which blocks antigen presentation, and expression of GM-CSF. Following intra-tumoral injection, OncoVEXGM-CSF is, therefore, intended to stimulate a GM-CSF-enhanced immune response to tumour antigens released by oncolysis. This aims to treat metastatic disease and reduce tumor recurrence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
